实用临床医药杂志
實用臨床醫藥雜誌
실용림상의약잡지
JOURNAL OF JIANGSU CLINICAL MEDICINE
2014年
16期
75-77
,共3页
重组人血管内皮抑制素%三维适形放疗%非小细胞肺癌%生存期%放射性肺损伤
重組人血管內皮抑製素%三維適形放療%非小細胞肺癌%生存期%放射性肺損傷
중조인혈관내피억제소%삼유괄형방료%비소세포폐암%생존기%방사성폐손상
recombinant human endostatin%three dimensional conformal radiotherapy%non-small cell lung cancer%survival time%radioactive lung injurl
目的：探讨重组人血管内皮抑制素联合三维适形放疗治疗局部晚期非小细胞肺癌（NSCLC）的疗效。方法选取经病理组织学或细胞学检查确诊的ⅢA ～ⅢB 期 NSCLC 患者78例，分为对照组和试验组，每组39例。对照组采用单纯三维适形放疗，试验组采用重组人血管内皮抑制素联合三维适形放疗。治疗2周期评价疗效及不良反应，至随访结束观察生存期。结果试验组的客观缓解率（RR）为69．2％，疾病控制率（DCR）为89．7％；对照组 RR 为33．3％，DCR 为71．8％。试验组的 RR、DCR 显著高于对照组（P ＜0．05或 P ＜0．01）。2组不良反应以贫血、恶心呕吐、白细胞减少、放射性肺损伤为主，均可耐受。至截止时间，试验组中位无进展生存期为8个月，中位生存期为13个月，对照组中位无进展生存期为5个月，中位生存期为9个月。结论重组人血管内皮抑制素联合三维适形放疗治疗晚期 NSCLC 的疗效优于单纯三维适形放疗，不良反应无明显增加。
目的：探討重組人血管內皮抑製素聯閤三維適形放療治療跼部晚期非小細胞肺癌（NSCLC）的療效。方法選取經病理組織學或細胞學檢查確診的ⅢA ～ⅢB 期 NSCLC 患者78例，分為對照組和試驗組，每組39例。對照組採用單純三維適形放療，試驗組採用重組人血管內皮抑製素聯閤三維適形放療。治療2週期評價療效及不良反應，至隨訪結束觀察生存期。結果試驗組的客觀緩解率（RR）為69．2％，疾病控製率（DCR）為89．7％；對照組 RR 為33．3％，DCR 為71．8％。試驗組的 RR、DCR 顯著高于對照組（P ＜0．05或 P ＜0．01）。2組不良反應以貧血、噁心嘔吐、白細胞減少、放射性肺損傷為主，均可耐受。至截止時間，試驗組中位無進展生存期為8箇月，中位生存期為13箇月，對照組中位無進展生存期為5箇月，中位生存期為9箇月。結論重組人血管內皮抑製素聯閤三維適形放療治療晚期 NSCLC 的療效優于單純三維適形放療，不良反應無明顯增加。
목적：탐토중조인혈관내피억제소연합삼유괄형방료치료국부만기비소세포폐암（NSCLC）적료효。방법선취경병리조직학혹세포학검사학진적ⅢA ～ⅢB 기 NSCLC 환자78례，분위대조조화시험조，매조39례。대조조채용단순삼유괄형방료，시험조채용중조인혈관내피억제소연합삼유괄형방료。치료2주기평개료효급불량반응，지수방결속관찰생존기。결과시험조적객관완해솔（RR）위69．2％，질병공제솔（DCR）위89．7％；대조조 RR 위33．3％，DCR 위71．8％。시험조적 RR、DCR 현저고우대조조（P ＜0．05혹 P ＜0．01）。2조불량반응이빈혈、악심구토、백세포감소、방사성폐손상위주，균가내수。지절지시간，시험조중위무진전생존기위8개월，중위생존기위13개월，대조조중위무진전생존기위5개월，중위생존기위9개월。결론중조인혈관내피억제소연합삼유괄형방료치료만기 NSCLC 적료효우우단순삼유괄형방료，불량반응무명현증가。
Objective To explore the clinical efficacy of recombinant human endostatin (en-dostar)combined with three dimensional conformal radiotherapy (3D-CRT)on treatment of patients with non-small cell lung cancer (NSCLC).Methods 78 patients with NSCLC in phase ⅢA ~ⅢB by histopathology and cytology were randomly divided into control group (treated with single 3D-CRT) and experiment group (treated with endostar and 3D-CRT),39 cases in each group.Clinical efficacy and adverse responses were evaluated after two cycles of treatment and survival time was observed until the end of follow-up.Results The objective remission rate (RR)and disease control rate (DCR)in experiment group were 69.2% and 89.7% respectively,which were evidently higher than the 33.3%and 71.8% in control group (P <0.05 or P <0.01).The main adverse responses in both groups were anemia,nausea and vomiting,leukopenia and radioactive lung injury and all were tolerable.Until the end of follow-up,the medium progression free survival time and medium survival time in experimental group were 8 and 13 months,and in control group were 5 and 9 months respectively.Conclusion Endostar combined with 3D-CRT are superior to single 3D-CRT without increasing adverse responses in the treatment of NSCLC.
